Physician profile
Nicholas Binder
NPI 1306076716
$3,441.46
in general payments reported to CMS, 2019-2025
21 companies · $1,069 in 2025
The $1,069 reported for 2025 was more than what 79% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $300 · 2020: $386 · 2021: $962 · 2022: $484 · 2023: $100 · 2024: $140 · 2025: $1,069.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,308.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,342.48 | 2019-2025 | Clareon, Hydrus Microstent, Rocklatan |
| Bausch & Lomb Americas INC. | $549.09 | 2024-2025 | Envista Envy Iol, Stellaris, Miebo |
| Sight Sciences, INC. | $297.99 | 2021-2024 | Omni Surgical System |
| Rxsight INC | $293.42 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Rxsight Injector Handpiece |
| Novartis Pharmaceuticals Corporation | $193.70 | 2020-2022 | |
| Allergan, INC. | $115.28 | 2020-2022 | |
| Oyster Point Pharma, INC. | $93.51 | 2022 | |
| Horizon Therapeutics Plc | $83.99 | 2021-2022 | |
| Aerie Pharmaceuticals, INC. | $66.80 | 2020-2021 | |
| Kala Pharmaceuticals, INC. | $65.95 | 2020-2021 | |
| Amgen INC. | $48.10 | 2025 | Tepezza |
| Ocular Therapeutix, INC. | $43.49 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $38.70 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $34.56 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $33.74 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $32.61 | 2022 | |
| Carl Zeiss Meditec USA, INC. | $29.84 | 2022 | |
| Abbvie INC. | $29.26 | 2022 | |
| Mallinckrodt Hospital Products INC. | $28.60 | 2025 | Acthar |
| Biohaven Pharmaceutical Holding Company Ltd. | $16.20 | 2022 | |
| Travere Therapeutics, INC. | $4.15 | 2019-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Binder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.